Cost-effectiveness of pembrolizumab as neoadjuvant therapy and in combination with standard of care (SOC) as adjuvant therapy for stage III-IVA resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC) in Switzerland
Claudine Bommer, Srushti Gotarkar, Burcu Akyol, Kian Farajkhah et autres